Statin-induced myopathies

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Toxicology

Background:

• Statins are primary treatments for hypercholesterolemia, a key atherosclerosis risk factor.
• Despite general safety, statins can cause myotoxicity, ranging from myalgia to rhabdomyolysis.
• Rhabdomyolysis is a severe statin adverse effect, potentially leading to renal failure and death.

Purpose of the Study:

• To review the pathophysiology of statin-induced myotoxicity.
• To discuss the prevention and treatment strategies for statin-related muscle damage.

Main Methods:

• Literature review focusing on the mechanisms of statin myotoxicity.
• Analysis of clinical trial definitions of statin toxicity.
• Examination of preventative and therapeutic interventions.

Main Results:

• Statin-induced myopathy involves multiple, not fully understood, pathophysiological mechanisms.
• Prevention strategies include using minimal effective statin doses and avoiding interacting medications.
• Discontinuation of statin therapy is the current primary treatment for diagnosed myopathy.

Conclusions:

• Understanding statin myotoxicity mechanisms is crucial for patient safety.
• Careful dosing and drug interaction awareness are key to preventing statin-related muscle issues.
• Prompt cessation of statins is essential for managing statin-induced myopathy.